StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Non-GAAP selling, general and administrative expenses by Year

Non-GAAP selling, general and administrative (SG&A) expenses ($M) ($M)

Gilead Sciences Non-GAAP selling, general and administrative expenses: $5,619M in FY2025, down 4.8% from a year earlier.

Latest, FY2025
5,619
Period ended Dec 31, 2025
Change on a year earlier
-4.8%
5,903 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Selling, general and administrative expenses | $ | 1,688 | $ | 1,852 | (9)% | $ | 5,619 | $ | 5,903 | (5)%”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up non-GAAP selling, general and administrative expenses

Cite this data

StockData. (2026). Gilead Sciences Non-GAAP selling, general and administrative expenses ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-sga

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.